Gevo, Inc. (GEVO)
Gevo, Inc. operates as a renewable fuels company. The company commercializes gasoline, jet fuel, and diesel fuel to achieve zero carbon emissions, and reduce greenhouse gas emissions with sustainable alternatives. Its products also include renewable biodiesel, isooctane, isobutanol, sustainable aviation fuel, isobutylene, ethanol, and animal feed.
Navios Maritime Partners L.P. (NMM)
Navios Maritime Partners L.P. owns and operates dry cargo vessels in Asia, Europe, North America, and Australia. The company offers seaborne transportation services for a range of dry cargo commodities, including iron ore, coal, grain, fertilizers, and containers, as well as charters its vessels under medium to long-term charters. As of March 24, 2021, it operated a fleet of 52 vessels.
MediaCo Holding Inc. (MDIA)
MediaCo Holding Inc. owns and operates radio stations in the United States. It operates in two segments, Radio and Outdoor Advertising. The Radio segment engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City metropolitan area. The Outdoor Advertising segment operates advertising displays, such as bulletins, posters, and digital billboards primarily in Kentucky, West Virginia, Florida, and Georgia. The company also offers digital advertising and event sponsorship services. As of December 31, 2020, it owned and operated approximately 3,532 billboard advertising displays.
Alcoa Corporation (AA)
Alcoa Corporation, together with its subsidiaries, produces and sells bauxite, alumina, and aluminum products in the United States, Spain, Australia, Brazil, Canada, and internationally. The company operates through three segments: Bauxite, Alumina, and Aluminum. It engages in bauxite mining operations; and processes bauxite into alumina and sells it to customers who process it into industrial chemical products, as well as aluminum smelting, casting, and rolling businesses.
Top Stock To Watch
Seelos Therapeutics, Inc. (SEEL)
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD).